A Phase 1/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Pancreatic Adenocarcinoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Patients must have pathologically confirmed pancreatic adenocarcinoma. 2) Received 4-6 months of induction chemotherapy with either fluorouracil, irinotecan, leucovorin and oxaliplatin (FOLFIRINOX) or gemcitabine/Abraxane, as per standard of care.

You may not be eligible for this study if the following are true:

  • 1) Patients who have completed induction chemotherapy less than 2 weeks or more than 8 weeks prior to study enrollment. 2) Patients who have not recovered from adverse events due to prior anti-cancer therapy. 3) Patients with mild reactions may be

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.